Check RXRX stock price, technical analysis, earnings beat, and forecast. Is RXRX stock a buy? Insights on Recursion’s AI-drug platform in 2026 biotech scene.
Introduction
Recursion Pharmaceuticals uses AI to find new drugs. It builds a platform for drug discovery. Investors track RXRX stock for AI-biotech promise and cash burn. Biotech funding tightens amid high rates.
RXRX stock heats up post-Q4 earnings beat. Sector eyes partnerships like Roche. This review eyes RXRX stock price swings and risks.
Latest Stock Price & Trend
RXRX stock closed at $3.52 on February 25, 2026. It gained 3.1% from prior day on earnings buzz.
Five-day up 10.6%. One-month rose 30.6% from $3.96 low.
Three-month up 36.4% peak. Six-month down 25.9%. YTD down 23.5%.
52-week low $3.79, high $12.36. Trend bullish short-term after bottom. Signals rebound potential for risk takers.
Technical Analysis
Support near $3.50-3.79 lows. Resistance at $4.00, 50-day MA. Support catches falls; resistance blocks rises.
RSI around 62, buy zone not overbought. Measures speed, spots extremes.
MACD buy signal at 0.06. Tracks momentum shifts.
Price above 20/50-day MAs, below 200-day. No cross yet. MAs guide trend direction.
Volume rose with price, backs move. High volume adds reliability.
Analyst Ratings & Price Targets
Consensus Buy from analysts. Average target $7.50, up 113% from $3.52. High $11, low $5.
BofA cut target on launch timing February 25. Firms like JPMorgan hold overweight.
Buy tilt shows growth faith. Helps gauge pro views.
Insider Activity
Q1-Q2 2025 net buys surged, ratio over 100%. Directors like Namandje Bumpus bought 142k shares.
Trend bullish, more buys than sells. Signals management bets on upside.
Valuation Analysis
No P/E due losses, EPS -$1.44 FY2025 improved. P/S high at 36x.
Revenue up 27% YoY to $74.7M. Cash $528M, debt low 0.1 equity. Runway to 2028.
Peers like NVCR similar cash burn. RXRX overvalued on sales, but platform justifies premium.
Recent Earnings & Catalysts
Q4 revenue $35.5M beat by 45%, EPS -$0.21 vs -$0.30 expected. FY revenue $74.7M up 27%.
Expenses cut: R&D down 2%, G&A 56%. Cash extends early 2028. Stock up 8.5% post-earnings.
Catalysts: NVIDIA GTC talk, Roche/Sanofi deals, AI platform advances. Earnings sparked rally.
Bullish Case
AI speeds discovery, cuts costs. Partnerships fuel revenue.
Bio space demand high for tech edge. Pipeline progress key.
Bearish Case
High burn risks dilution. Competition from big pharma AI.
No approvals yet, regulatory hurdles. Short interest notable.
Market Sentiment
Short interest data shows interest, details vary. Institutions hold steady.
Retail loves momentum plays. Optimistic post-earnings.
Short-Term Outlook
Buy signals on MACD/RSI. Volume supports gains. Momentum favors upside near-term.
Medium to Long-Term Outlook
Platform scales with data. Biotech AI grows fast. Position early but cash watch needed. Accumulate on weakness for believers.
FAQ
Is RXRX stock a buy right now? Buy per analysts; high risk/reward.
What is the price target for RXRX stock? $7.50 average, to $11.
What are major risks for RXRX stock? Cash burn, no profits, competition.
RXRX earnings impact? Q4 beat lifted shares 8.5%.
RXRX forecast long-term? Strong if partnerships deliver.
Suggestions
- Compare with Opendoor stocks
- See our Recursion partner Roche analysis
- Read AI drug discovery sector guide
Final Balanced Conclusion
Watchlist RXRX stock. Earnings beat excites, but profitability path key. High volatility suits aggressive investors.
Disclaimer: This article is for informational purposes only and not financial advice.